Home › Funds › Montaka Global Pty Ltd › MRNA
Montaka Global Pty Ltd position in MRNA
MODERNA INC · Health Care
Montaka Global Pty Ltd reported holding 11,775 shares of MRNA (MODERNA INC) in its Q3 2026 13F filing — a position valued at US$2.3M, representing 0.98% of its reported portfolio and ranking #25 among its reported holdings. Montaka Global Pty Ltd has disclosed MRNA holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-05 · Source: SEC EDGAR Form 13F-HR
How Montaka Global Pty Ltd's MRNA position evolved
Montaka Global Pty Ltd first disclosed a stake in MRNA in Q4 2025 at 13,575 shares (US$400K). The position peaked in Q3 2026 at 11,775 shares, worth US$2.3M. Across 4 filings, Montaka Global Pty Ltd increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 11,775 shares valued at US$2.3M — a reduction of -8,175 shares quarter over quarter.. Notable position changes include a 48% increase in Q1 2026 (shares rose 38% over the following quarter), a 41% trim in Q3 2026 (shares rose 34% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 13.57K | $400.33K | New |
| Q1 2026 | 20.06K | $1.02M | Add |
| Q2 2026 | 19.95K | $1.40M | Reduce |
| Q3 2026 | 11.78K | $2.27M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MRNA and 13F data
MRNA (MODERNA INC) is a Health Care company. 37 other funds we track also report a position in MRNA — the largest reported positions include Baillie Gifford & Co (US$1.28B), Theleme Partners LLP (US$564.3M), BANQUE PICTET & CIE SA (US$414.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MRNA
- Baillie Gifford & Co 18.21M sh · $1.28B · Q2 2026
- Theleme Partners LLP 8.06M sh · $564.27M · Q2 2026
- BANQUE PICTET & CIE SA 2.15M sh · $414.27M · Q3 2026
- Flagship Pioneering, LLC 4.63M sh · $324.39M · Q2 2026
- Douglas Lane & Associates, LLC 1.16M sh · $223.56M · Q3 2026
- Beau Ventures, LLc 1.00M sh · $192.58M · Q3 2026
- Merck & Co., Inc. 2.31M sh · $161.64M · Q2 2026
- Baron Funds 1.99M sh · $139.32M · Q2 2026
- BAMCO INC /NY/ 1.99M sh · $139.32M · Q2 2026
- IMC-Chicago, LLC 1.70M sh · $119.21M · Q2 2026
More on Montaka Global Pty Ltd
FAQ
How long has Montaka Global Pty Ltd held MRNA?
Montaka Global Pty Ltd has disclosed MRNA holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Montaka Global Pty Ltd's current position in MRNA?
As of Q3 2026, Montaka Global Pty Ltd holds 11.78K shares of MRNA (MODERNA INC), valued at $2.27M, representing 0.98% of its reported portfolio and ranking #25.
Has Montaka Global Pty Ltd been buying or selling MRNA?
In the latest 13F filing (Q3 2026), Montaka Global Pty Ltd reduced its position in MRNA. The position peaked in Q3 2026 at 11.78K shares.
Which other funds hold MRNA?
Other major institutional holders of MRNA include Baillie Gifford & Co, Theleme Partners LLP, BANQUE PICTET & CIE SA, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.